Experimental Cancer Therapeutics Targeting the Hepatocyte Growth Factor/Met Signaling Pathway

HGF and c-Met Targeted Drug Development for Oncology

The table below lists clinical trials for cancer therapeutics targeting the hepatocyte growth factor (HGF)/Met signaling pathway. This page is maintained by Don Bottaro in the Urologic Oncology Branch, CCR/NCI, and should be cited as:

Cecchi F, Wright C, Bottaro DP. Experimental Cancer Therapeutics Targeting the Hepatocyte Growth Factor/Met Signaling Pathway. Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 USA. URL: https://ccrod.cancer.gov/confluence/display/CCRHGF/Home

The original source for this page was published in the May 2010 issue of European Journal of Cancer, vol 7, pp 1260-70.

Each of the column headings (Drug, Design, Phase, etc.) can be toggled to reorder the entire list by the column content.

UCSD Signaling Gateway

Additional information on the HGF/Met signaling pathway can be found on the University of California San Diego (UCSD) Signaling Gateway.

Drug	Design	Phase	Status	Patient Population	Combinations	Clinical Trial	Results
Rilotumumab (AMG 102)	Safety	Ib/II	Completed	Non-Small Cell Lung Cancer (NSCLC)	Cisplatin/Etoposide	NCT00791154
Rilotumumab (AMG 102)	Safety/Efficacy	I/II	Completed	Metastatic Colorectal Cancer (mCRC), wild type KRAS	Panitumumab	NCT00788957
Rilotumumab (AMG 102)	Safety/Efficacy	I/II	Completed	Castration-Resistant Prostate Cancer (CRPC)	Mitoxantrone/Prednisone	NCT00770848
Rilotumumab (AMG 102)	Safety/Efficacy	II	Completed	Renal Cell Carcinoma (RCC)		NCT00422019	BJU Int 2011
Rilotumumab (AMG 102)	Safety/Efficacy	II	Active, not recruiting	Advanced Malignant Glioma		NCT00427440	Neuro Oncol 2011
Rilotumumab (AMG 102)	Safety/Efficacy	I/II	Completed	Locally Advanced/Metastatic Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma	Capecitabine/Epirubicin/Cisplatin (ECX)	NCT00719550	ASCO 2012 ESMO 2012a ESMO 2012b
Rilotumumab (AMG 102)	Safety	I/II	Recruiting	NSCLC	Erlotinib	NCT01233687
Rilotumumab (AMG 102)	Safety/Efficacy	II	Completed	Recurrent Malignant Glioma	Bevacizumab	NCT01113398	ASCO 2012 NCT01113398
Rilotumumab (AMG 102)	Efficacy	II	Recruiting	Advanced Gastroesophageal Adenocarcinoma	Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX)	NCT01443065
Rilotumumab (AMG 102)	Safety	II	Completed	Persistent/Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer		NCT01039207
Rilotumumab (AMG 102)	Treatment	II	Withdrawn	Malignant Mesothelioma	Pemetrexed Disodium and Cisplatin	NCT01105390
Rilotumumab (AMG 102)	Efficacy	III	Terminated	Locally Advanced/MetastaticGastric or Esophagogastric Junction (EGJ) Adenocarcinoma	Randomized vs placebo	NCT01697072	ASCO 2013
Rilotumumab (AMG 102)	Safety/Efficacy	I/Ib	Completed	Japanese Subjects with Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ		NCT01791374
Rilotumumab (AMG 102)	Efficacy	III	Terminated	Gastric Cancer	+ Cisplatin and Capecitabine vs placebo	NCT02137343
Onartuzumab (MetMAb)	Safety	I	Completed	Advanced Solid Malignancies	Bevacizumab	NCT01068977	AACR 2010 ASCO 2010 EMSO 2010 AACR 2011
Onartuzumab (MetMAb)	Efficacy	II	Active, results reported	NSCLC	Erlotinib	NCT00854308	ClinicalTrials.gov JCO 2013
Onartuzumab (MetMAb)	Efficacy	II	Completed	Metastatic/Recurrent, Triple-Negative Breast Cancer	Bevacizumab and Paclitaxel	NCT01186991	Anal Oncol 2015
Onartuzumab (MetMAb)	Efficacy	II	Active, not recruiting	mCRC	FOLFOX/Bevacizumab	NCT01418222	ASCO 2012
Onartuzumab (MetMAb)	Safety/Efficacy	II	Active, not recruiting	NSCLC	Bevacizumab/Platinum/Paclitaxel and Pemetrexed/Platinum	NCT01496742	EMSO 2012
Onartuzumab (MetMAb)	Safety/Efficacy	II	Active, not recruiting	NSCLC	Paclitaxel/Platinum	NCT01519804	EMSO 2012
Onartuzumab (MetMAb)	Safety/Efficacy	II	Not yet recruiting	Gastric cancer	mFOLFOX6	NCT01590719
Onartuzumab (MetMAb)	Safety/Efficacy	III	Recruiting	NSCLC	Tarceva (Erlotinib)	NCT01456325	Press Release
Onartuzumab (MetMAb)	Safety/Efficacy	II	Recruiting	Recurrent Glioblastoma	+Bevacizumab vs Bevacizumab alone vs Onartuzumab monotherapy, Randomized	NCT01632228
Onartuzumab (MetMAb)	Safety/Efficacy	III	Recruiting	Metastatic Gastric cancer, HER2-, Met+	mFOLFOX6	NCT01662869	ASCO 2013
Onartuzumab (MetMAb)	Safety/PK	Ib	Recruiting	Advanced Solid Malignancies	+Vemurafenib, +Cobimetinib, +Vemurafenib and Cobimetinib	NCT01974258
Onartuzumab (MetMAb)	Safety/Efficacy	I	Recruiting	Chinese Patients with Locally Advanced or Metastatic Solid Tumors		NCT02031731
Onartuzumab (MetMAb)	Safety/PK	Ib	Recruiting	Advanced HCC	alone or +Sorafenib	NCT01897038
Onartuzumab (MetMAb)	Safety/Efficacy	III	Recruiting	Met+, Stage IIIb or IV NSCLC with Activating EGFR Mutation	+Erlotinib	NCT01887886
Onartuzumab (MetMAb)	Efficacy	III	Recruiting	Met+, Incurable Stage IIIb or IV NSCLC	+Erlotinib	NCT02031744
Ficlatuzumab (AV-299)	Safety/Efficacy	I	Terminated	Glioblastoma		NCT01189513
Ficlatuzumab (AV-299)	Safety/Tolerability	I	Completed	Advanced/Metastatic Solid Malignancies		NCT00969410	EMSO 2012 Clin Cancer Res 2014
Ficlatuzumab (AV-299)	Safety/Efficacy	I/II	Completed	NSCLC	Gefitinib	NCT01039948	EMSO 2010
Ficlatuzumab (AV-299)	Safety	I	Active	Relapsed/Refractory Solid Malignancies	Erlotinib	NCT00725634
Ficlatuzumab (AV-299)	Safety/Efficacy	I	Active, not recruiting	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	+Cetuximab	NCT02277197
Ficlatuzumab (AV-299)	Safety/Efficacy	I	Terminated	Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	+Cisplatin +Intensity Modulated Radiotherapy	NCT02277184
SAIT301	Safety	I	Recruiting	Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types		NCT02296879
TAK-701 (HuL2G7)	Safety/Tolerability/Pharmacokinetics	I	Completed	Non-Hematologic Malignancies		NCT00831896
AMG 337	Safety	I	Recruiting	Advanced Solid Malignancies		NCT01253707
AMG 337	Efficacy	II	Not yet recruiting	MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors		NCT02016534
AMG 337	Safety/Efficacy	I/II	Recruiting	Advanced solid tumor (Pahse I) Gastric/Esophageal Adenocarcinoma or Other Solid Tumor (Phase II)		NCT02096666
AMG 337	Safety/Efficacy	I/II	Not yet recruiting	Advanced Stomach or Esophageal Cancer	Fluorouracil, Oxaliplatin, Leucovorin	NCT02344810
AMG 208	Safety	I	Active, not recruiting	Advanced Solid Malignancies		NCT00813384	J Clin Oncol 2014
Tivantinib (ARQ 197) Notice	Safety/Efficacy	I	Completed	Advanced Solid Malignancies		NCT00612209	J Clin Oncol 2011
Tivantinib (ARQ 197) Notice	Bio-availability	I	Completed	Advanced Solid Malignancies		NCT01149720
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Completed	Gastric Cancer (GC)		NCT01152645
Tivantinib (ARQ 197) Notice	Safety/Efficacy	I/II	Active, not recruiting	CRC, wild type KRAS	Irinotecan/Cetuximab	NCT01075048	ASCO 2013
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Active, not recruiting	Advanced/Metastatic NSCLC, KRAS mutation +	Erlotinib	NCT01395758
Tivantinib (ARQ 197) Notice	Safety	I	Completed	Advanced Solid Malignancies	Gemcitabine	NCT00874042	EMSO 2012
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Completed	Hepatocellular Carcinoma (HCC)		NCT00988741	ASCO 2012 EMSO 2012a EMSO 2012b Lancet Oncol 2013
Tivantinib (ARQ 197) Notice	Safety	I	Active, not recruiting	Advanced Solid Malignancies	Sorafenib	NCT00827177	EMSO 2012
Tivantinib (ARQ 197) Notice	Pharmacokinetics	I	Completed	Healthy Volunteer		NCT00651638
Tivantinib (ARQ 197) Notice	Safety	I	Completed	NSCLC	Erlotinib	NCT01251796	EMSO 2012
Tivantinib (ARQ 197) Notice	Safety	I	Completed	Advanced/Recurrent NSCLC	Erlotinib	NCT01069757
Tivantinib (ARQ 197) Notice	Safety/Efficacy	III	Active, not recruiting	Non-Squamous NSCLC	Erlotinib	NCT01244191	Clin Lung Cancer 2012
Tivantinib (ARQ 197) Notice	Safety/Tolerability	I	Completed	Metastatic Solid Malignancies		NCT00302172	EMSO 2012 Clin Can Res 2011
Tivantinib (ARQ 197) Notice	Efficacy	II	Completed	Unresectable Locally Advanced/Metastatic Pancreatic Adenocarcinoma	Gemcitabine	NCT00558207
Tivantinib (ARQ 197) Notice	Safety/Efficacy	I	Completed	Advanced Solid Malignancies	Erlotinib	NCT00612703	EMSO 2012 Cancer 2012
Tivantinib (ARQ 197) Notice	Efficacy	II	Withdrawn	Locally Advanced/Metastatic GC	Oxaliplatin/Capecitabine/Irinotecan	NCT01070290
Tivantinib (ARQ 197) Notice	Safety	I	Recruiting	Advanced Solid Malignancies	Pazopanib	NCT01468922
Tivantinib (ARQ 197) Notice	Safety	I	Completed	HCC (Cirrhotic Patients)	Erlotinib	NCT00802555	Br J Cancer 2013
Tivantinib (ARQ 197) Notice	Efficacy	II	Completed	Advanced/Metastatic NSCLC	Erlotinib	NCT00777309	J Clin Oncol 2011
Tivantinib (ARQ 197) Notice	Pharmacokinetics	I	Completed	Healthy Volunteer		NCT00658554
Tivantinib (ARQ 197) Notice	Safety/Tolerability	I	Completed	Advanced Solid/Recurrent Malignancies		NCT00609921	Ann Oncol 2013
Tivantinib (ARQ 197) Notice	Efficacy	III	Active, not recruiting	Advanced/Metastatic Non Squamous NSCLC wild type EGFR	Erlotinib	NCT01377376
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Completed	Refractory Germ Cell Tumors		NCT01055067	Invest New Drugs 2013
Tivantinib (ARQ 197) Notice	Safety/Efficacy	I/II	Recruiting	Extension Protocol; Subjects Who Were Previously Enrolled in Other ARQ 197 Studies		NCT01178411
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Completed	Microphthalmia Transcription Factor-Associated Tumors (MiT) Associated with Renal Cell Carcinoma (RCC)/Alveolar Soft Part Sarcoma (ASPS)/Clear Cell Carcinoma (CCS)		NCT00557609	Cancer 2012
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Active, not recruiting	Relapsed Multiple Myeloma		NCT01447914
Tivantinib (ARQ 197) Notice	Safety/Efficacy	II	Active, not recruiting	Advanced or Metastatic EGFR mutation-positive NSCLC	Erlotinib	NCT01580735
Tivantinib (ARQ 197) Notice	Pharmacokinetics	I	Completed	Solid Tumors	Omeprazole, s-Warfarin, Caffeine, Midazolam, Digoxin	NCT01517399
Tivantinib (ARQ 197) Notice	Treatment	II	Completed	Recurrent or Metastatic Breast Cancer		NCT01575522	NCT01575522
Tivantinib (ARQ 197) Notice	Treatment	II	Recruiting	Metastatic Prostate Cancer		NCT01519414
Tivantinib (ARQ 197) Notice	Efficacy	I/II	Recruiting	Advanced Solid Tumors, First Line Metastatic Gastroesophageal Cancer	FOLFOX	NCT01611857	ASCO 2013
Tivantinib (ARQ 197) Notice	Efficacy	II	Completed	Triple Negative Breast cancer		NCT01542996	NCT01542996
Tivantinib (ARQ 197) Notice	Safety	I	Completed	Effect of Tivantinib on QTC Interval in Cancer Subjects		NCT01699061
Tivantinib (ARQ 197) Notice	Safety	I	Recruiting	Younger Patients with Relapsed or Refractory Solid Tumors		NCT01725191
Tivantinib (ARQ 197) Notice	Efficacy	II	Recruiting	Metastatic or Recurrent or Inoperable Squamous Cell Carcinoma of the Head and Neck (SCCHN)	+ Cetuximab vs Cetuximab, Randomized	NCT01696955
Tivantinib (ARQ 197) Notice	Safety	I	Recruiting	Metastatic or Unresectable Solid Tumors	Temsirolimus	NCT01625156
Tivantinib (ARQ 197) Notice	Efficacy	II	Suspended	Metastatic or Locally Advanced Unresectable RCC	Erlotinib	NCT01688973
Tivantinib (ARQ 197) Notice	Safety/Efficacy	I	Recruiting	Advanced or Metastatic Solid Tumors or Recurrent Small Cell Lung Cancer	Topotecan	NCT01654965
Tivantinib (ARQ 197) Notice	Safety	I	Recruiting	Advanced HCC		NCT01656265
Tivantinib (ARQ 197) Notice	Efficacy	III	Recruiting	Hepatocellular Carcinoma		NCT01755767	ASCO 2013
Tivantinib (ARQ 197) Notice	Efficacy	II	Recruiting	EGFR-Inhbitor Resistant, KRAS-Wildtype Advanced or Metastatic Colorectal Cancer	+Cetuximab	NCT01892527
Tivantinib (ARQ 197) Notice	Safety	I	Recruiting	Metastatic or Unresectable Solid Tumors	+Bevacizumab	NCT01749384
Tivantinib (ARQ 197) Notice	Efficacy	II	Recruiting	Patients with Previously Treated Mesothelioma		NCT01861301
Tivantinib (ARQ 197) Notice	Efficacy	III	Recruiting	Met+ Inoperable HCC with One Prior Sorafenib Therapy		NCT02029157
BMS-777607 (ASLAN002)	Safety/Efficacy	I/II	Completed	Advanced/Metastatic Solid Malignancies, CRPC, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Papillary Renal-Cell Carcinoma (PRCC)		NCT00605618
BMS-777607 (ASLAN002)	Safety	I	Recruiting	Advanced or Metastatic Solid Tumors		NCT01721148
Golvatinib E7050	Efficacy	I/II	Recruiting	Advanced Solid Malignancies, Glioblastoma, Unresectable Stage III/IV Melanoma	Lenvatinib	NCT01433991
Golvatinib E7050	Safety/Efficacy	I	Recruiting	Solid Tumors		NCT01428141
Golvatinib E7050	Safety/Efficacy	I/II	Terminated	Advanced or Metastatic Solid Tumors & Previously Untreated Gastric Cancer (GC)	with Cisplatin Capecitabine vs Cisplatin Capecitabine alone, Randomized	NCT01355302
Golvatinib E7050	Safety/Efficacy	I/II	Completed	Advanced Solid Tumors		NCT00921869
Golvatinib E7050	Safety/Efficacy	I/II	Active, not recruiting	Platinum-Resistant SCCHN	+ Cetuximab vs Cetuximab alone, Randomized	NCT01332266
Golvatinib E7050	Safety/Efficacy	I/II	Recruiting	HCC	+ Sorafenib vs Sorafenib alone, Randomized	NCT01271504
Golvatinib E7050	Safety	I	Completed	Advanced Solid Tumors		NCT00869895	ASCO 2012
EMD1214063	Safety	I	Completed	Advanced Solid Malignancies		NCT01014936	EMSO 2012 ASCO 2013
EMD1204831	Safety	I	Terminated	Advanced Solid Malignancies		NCT01110083	ASCO 2012
Foretinib (GSK1363089)	Safety/Efficacy	II	Completed	Recurrent/Metastatic SCCHN		NCT00725764
Foretinib (GSK1363089)	Safety	I	Completed	Advanced Solid Malignancies		NCT00743067	Clin Can Res 2010
Foretinib (GSK1363089)	Safety/Efficacy	II	Completed	Metastatic Gastric Carcinoma (mGC)		NCT00725712
Foretinib (GSK1363089)	Bio-availability	I	Completed	Advanced Solid Malignancies		NCT00742261
Foretinib (GSK1363089)	Safety/Efficacy	I	Active, not recruiting	HCC		NCT00920192
Foretinib (GSK1363089)	Safety/Efficacy	II	Completed	PRCC		NCT00726323	ASCO 2012 J Clin Oncol 2012
Foretinib (GSK1363089)	Safety/Efficacy	I/II	Active, not recruiting	Locally Advanced/Metastatic NSCLC	Erlotinib	NCT01068587
Foretinib (GSK1363089)	Safety/Efficacy	I/II	Active, not recruiting	HER2 Over-Expressing Metastatic Breast Cancer	Lapatinib	NCT01138384
Foretinib (GSK1363089)	Safety/Efficacy	II	Completed	ER, PR and HER2 negative Breast Cancer		NCT01147484	ASCO 2012
Foretinib (GSK1363089)	Safety	I	Completed	Solid Tumors		NCT00742131
Foretinib (GSK1363089)	Efficacy	II	Not yet open	Genomic Subpopulations of NSCLC		NCT02034097
INCB28060 (INC280)	Safety/Tolerability	I	Active, Not Recruiting	Advanced Solid Malignancies		NCT01072266	ASCO 2011
INCB28060 (INC280)	Treatment	I	Recruiting	Solid tumors		NCT01324479
INCB28060 (INC280)	Safety	I	Recruiting	Japanese Patients with Advanced Solid Tumors		NCT01546428
INCB28060 (INC280)	Safety/Efficacy	IB/II	Active, Not Recruiting	NSCLC, EGFR-mutated, c-MET-amplified, EGFR-inhibitor insensitive	Gefitinib	NCT01610336
INCB28060 (INC280)	Safety/Tolerability	I	Recruiting	c-MET Dependent Advanced Solid Tumors		NCT01324479
INCB28060 (INC280)	Safety/Efficacy	II	Recruiting	Advanced HCC With c-MET Dysregulation		NCT01737827	ASCO 2015
INCB28060 (INC280)	Safety/Efficacy	Ib/II	Recruiting	Recurrent Glioblastoma	+Buparlisib	NCT01870726
INCB28060 (INC280)	Safety Efficacy	II	Suspended	Advanced HCC After Progression or Sorafenib Intolerance		NCT01964235
INCB28060 (INC280)	Safety	I	Recruiting	Met+ NSCLC	+Erlotinib	NCT01911507
INCB28060 (INC280)	Efficacy	II	Recruiting	Papillary RCC		NCT02019693
INCB28060 (INC280)	Safety/Efficacy	II	Not yet Recruiting	Chinese Patients with Advanced NSCLC	multi-arm + AUY922, BYL719, LDK378, MEK162	NCT02276027
INCB28060 (INC280)	Efficacy	II	Recruiting	Advanced NSCLC Patients that have Received 1 or 2 Prior Lines of Therapy		NCT02414139
NCB28060 (INC280)	Safety/Pharmacokinetics/Efficacy	I/II	Recruiting	Squamous Cell Carcinoma of Head and Neck (Phase I) Metastatic Colorectal Cancer (Phase II)	Cetuximab	NCT02205398
NCB28060 (INC280)	Drug-drug Interaction: Pharmacokinetics of Midazolam and Caffiene	I	Not yet Recruiting	Patients with Met-dysregulated Advanced Solid Tumors	Midazolam, Caffiene	NCT02520752
NCB28060 (INC280)	Drug-drug Interaction: Pharmacokinetics of Digoxin and Rosuvastatin	I	Not yet Recruiting	Patients with Met-dysregulated Advanced Solid Tumors	Digoxin, Rosuvastatin	NCT02626234
LY2801653	Safety/Tolerability	I	Recruiting	Advanced and/or Metastatic Cancer		NCT01285037	Invest New Drugs 2013
LY2801653	PK/radiolabeled	I	Completed	Healthy Participants		NCT01981408
MK8033	Safety	I	Completed	Advanced Solid Malignancies	Omeprazole	NCT00559182
Amuvatinib (MP470)	Safety	I	Completed	Advanced Solid Malignancies		NCT00894894	Cancer Chemother Pharmacol 2013
Amuvatinib (MP470)	Safety/Efficacy	I	Completed	Advanced Solid Malignancies	Topotecan/Docetaxel/Erlotinib/Paclitaxel/ Carboplatin/Etoposide	NCT00881166
Amuvatinib (MP470)	Efficacy	II	Active, not recruiting	SCLC	Platinum/Etoposide	NCT01357395	Press Release
Amuvatinib (MP470)	Safety/PK/Pharmacodynamics	I	Terminated prior to activation	Metastatic Solid Malignancies/Lymphoma		NCT00504205
MGCD265	Safety/Efficacy	I/II	Recruiting	Advanced Malignancies/NSCLC	Erlotinib/Docetaxel	NCT00975767
MGCD265	Safety	I	Recruiting	Advanced Solid Malignancies		NCT00697632
MGCD265	Safety	I	Completed	Advanced Solid Malignancies		NCT00679133
MGCD265	Safety	I	Completed	Healthy Subjects in Fasting State		NCT01930006
MK2461	Safety/Efficacy	I/II	Completed	Advanced Solid Malignancies		NCT00496353
MK2461	Safety	I	Completed	Advanced Solid Malignancies		NCT00518739	ASCO 2008
Crizotinib (PF02341066)^**	PK	I	Completed	Subjects With Impaired Renal Function		NCT01419041
Crizotinib (PF02341066)^**	Safety/PK/PD	I	Withdrawn prior to activation	Advanced Solid Malignancies	VEGF Inhibitor Combinations	NCT01441388
Crizotinib (PF02341066)^**	Safety/Efficacy	IB	Recruiting	Anaplastic Lymphoma Kinase (ALK+) Tumors		NCT01121588
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Japanese Healthy Male Volunteers		NCT01250730	ClinicalTrials.gov
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Healthy Volunteer		NCT01297595	ClinicalTrials.gov
Crizotinib (PF02341066)^**	Safety/Efficacy	I/II	Active, not recruiting	NSCLC	Erlotinib	NCT00965731	ASCO 2012
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Healthy Volunteer		NCT01168934	ClinicalTrials.gov
Crizotinib (PF02341066)^**	Safety/Efficacy	I	Completed, results reported	NSCLC	Dacomitinib	NCT01121575	ClinicalTrials.gov
Crizotinib (PF02341066)^**	PK - [14C]PF 02341066	I	Completed, results reported	Healthy Male Volunteer		NCT01082380	ClinicalTrials.gov
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Healthy Volunteer	Ketoconazole	NCT01149785	ClinicalTrials.gov
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Healthy Volunteer	Rifampin	NCT01147055	ClinicalTrials.gov
Crizotinib (PF02341066)^**	PK	I	Completed, results reported	Healthy Volunteer		NCT01154218	ClinicalTrials.gov
Crizotinib (PF02341066)^**	Safety	I	Recruiting	Advanced Solid Malignancies		NCT00585195	ASCO 2013 ASCO 2013 New Engl J Med 2010 Lancet Oncol 2011 J Clin Oncol 2011 Lancet Oncol 2012
Crizotinib (PF02341066)^**	Safety/Efficacy	III	Completed	NSCLC, ALK+	Pemetrexed/Docetaxel	NCT00932893	ASCO 2013 ASCO 2013 New Engl J Med 2013 NCT00932893
Crizotinib (PF02341066)^**	Safety/PK	I/II	Recruiting	Relapsed/Refractory Solid Malignancies or Anaplastic Large Cell Lymphoma (Young Population)		NCT00939770	Lancet Oncol 2013
Crizotinib (PF02341066)^**	Safety/Efficacy	II	Recruiting	NSCLC, ALK+		NCT00932451	Expert Rev Anticancer Ther 2012
Crizotinib (PF02341066)^**	Bioavailability	I	Completed, results reported	Healthy Volunteer		NCT00939731	ClinicalTrials.gov
Crizotinib (PF02341066)^**	Taste Assessment	I	Completed	Healthy Volunteer		NCT01125904
Crizotinib (PF02341066)^**	Safety	I	Recruiting	NSCLC	Dacomitinib	NCT01441128
Crizotinib (PF02341066)^**	Obtain tissue specimens to identify molecular determinants of acquired resistance		Recruiting	NSCLC, ALK+		NCT01300429
Crizotinib (PF02341066)^**	Safety/Efficacy	III	Recruiting	Recurrent/Metastatic Non-Squamous Cell Carcinoma of the Lung ALK+		NCT01154140	Expert Rev Anticancer Ther 2012
Crizotinib (PF02341066)^**	Safety/Efficacy	I/II	Active, Not recruiting	NSCLC	Erlotinib	NCT00965731	NCT00965731
Crizotinib (PF02341066)^**	Safety/Efficacy	I	Recruiting	Advanced Malignancies	Pemetrexed or Pazopanib	NCT01548144
Crizotinib (PF02341066)^**	PK	I	Completed	Healthy Volunteers	Esomeprazole	NCT01549574
Crizotinib (PF02341066)^**	PK	I	Recruiting	Advanced Cancer Patients with Hepatic Impairment		NCT01576406
Crizotinib (PF02341066)^**	Safety/Efficacy	I/II	Recruiting	NSCLC	HSP90 Inhibitor AT13387	NCT01712217
Crizotinib (PF02341066)^**	Safety/Efficacy	II	Recruiting	Altered ALK and/or MET in Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Inflammatory Myfibroblastic Tumor, PRCC Type 1, Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Alveolar Rhabdomyosarcoma		NCT01524926
Crizotinib (PF02341066)^**	Safety/Tolerability	I	Not Yet Recruiting	Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Cyclophosphamide, Dexrazoxane, Doxorubicin, Topotecan, Vincristine	NCT01606878
Crizotinib (PF02341066)^**	Safety/Efficacy	I	Recruiting	Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Pediatric	Dasatinib	NCT01644773
Crizotinib (PF02341066)^**	Surveillance	IV	Invitation Only	Regulatory Post Marketing Commitment Plan		NCT01597258
Crizotinib (PF02341066)^**	Safety/Efficacy	I	Recruiting	Advanced Malignancies	Vemurafenib, Sorafenib	NCT01531361
Crizotinib (PF02341066)^**	Safety/Efficacy	II	Recruiting	Met-positive Gastric Adenocarcinoma as Third-line Therapy		NCT02435108
Crizotinib (PF02341066)^**	Safety/Efficacy	II	Recruiting	Met or Ron-positive Metastatic Urothelial Cancer		NCT02612194
Crizotinib (PF02341066)^**	Efficacy	II	Recruiting	Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) That Has Progressed After Crizotinib	+ Pemetrexed Disodium	NCT02134912
Crizotinib (PF02341066)^**	Safety	I	Recruiting	Advanced Solid Tumors	+ axitinib	NCT01999972
PF-04217903	Safety/Efficacy	I	Completed, results reported	Advanced Solid Malignancies		NCT00706355	ClinicalTrials.gov
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Active, not recruiting	mCRPC		NCT01428219	ASCO 2013
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Recruiting	Carcinoid/Pancreatic Neuroendocrine Tumor		NCT01466036
Cabozantinib (XL184) Cometriq	Efficacy	II	Recruiting	Breast Cancer, ER+/PR+and HER2-		NCT01441947
Cabozantinib (XL184) Cometriq	Safety/Efficacy	I	Completed	mCRPC		NCT01347788
Cabozantinib (XL184) Cometriq	Safety	I	Completed	Advanced Solid Malignancies		NCT00215605	ASCO 2013 J Clin Oncol 2011
Cabozantinib (XL184) Cometriq	Randomized Discontinuation Trial	II	Completed	Advanced Solid Malignancies		NCT00940225	ASCO 2013 ASCO 2013 J Clin Oncol 2013
Cabozantinib (XL184) Cometriq	Efficacy	III	Active, not recruiting	Metastatic Medullary Thyroid Cancer (MTC)		NCT00704730	ASCO 2012 EMSO 2012 ASCO 2013 J Clin Oncol 2013 NCT Results
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Completed	Glioblastoma Multiforme		NCT00704288
Cabozantinib (XL184) Cometriq	Safety/Efficacy	I/II	Completed	NSCLC	Erlotinib	NCT00596648
Cabozantinib (XL184) Cometriq	Drug-Drug Interaction Safety Study	I	Completed	Advanced Solid Malignancies	Rosiglitazone	NCT01100619
Cabozantinib (XL184) Cometriq	Safety	I	Completed	Glioblastoma	Temozolomide/Radiation Therapy	NCT00960492
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Completed	Grade IV Astrocytic Tumor		NCT01068782
Cabozantinib (XL184) Cometriq	Safety	I	Completed	Advanced/Metastatic Solid Malignancies (Japanese population)		NCT01018745
Cabozantinib (XL184) Cometriq	Safety/Efficacy	I	Recruiting	Multiple Myeloma with Bone Disease		NCT01582295
Cabozantinib (XL184) Cometriq	Efficacy	I	Active, not recruiting	Post-Chemo Castration-Resistant Prostate Cancer	Abiraterone	NCT01574937
Cabozantinib (XL184) Cometriq	Efficacy	II	Active, not recruiting	Castration-Resistant Prostate Cancer with Bone Metastases		NCT01599793	ASCO 2012 EMSO 2012
Cabozantinib (XL184) Cometriq	Safety/Pharmacokinetics	I	Completed	Hepatic Impaired Adult Subjects		NCT01493869
Cabozantinib (XL184) Cometriq	Safety/Efficacy	III	Active, not Recruiting	Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone or MDV3100	Prednisone	NCT01605227	Press Release 2014
Cabozantinib (XL184) Cometriq	Safety	I	Active, not recruiting	Japanese Subjects with Advanced Cancer		NCT01553656	EMSO 2012
Cabozantinib (XL184) Cometriq	Safety/Efficacy	III	Terminated	Previously Treated, Symptomatic Castration-Resistant Prostate Cancer	Mitoxantrone/Prednisone	NCT01522443	Press Release 2014
Cabozantinib (XL184) Cometriq	Efficacy	II	Suspended	Solid tumors		NCT01588821
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Recruiting	Androgen-Dependent Metastatic Prostate Cancer	Androgen Ablation Therapy	NCT01630590
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Recruiting	Advanced NSCLC, KIF5B/RET+		NCT01639508	ASCO 2013 Cancer Discov 2013
Cabozantinib (XL184) Cometriq	Efficacy	II	Active, not recruiting	Stage IV NSCLC, EGFR Wild-Type	Erlotinib	NCT01708954
Cabozantinib (XL184) Cometriq	Efficacy		Recruiting	CRPC		NCT01703065
Cabozantinib (XL184) Cometriq	Efficacy	II	Active, not recruiting	Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube, or Peritoneal Cancer	Randomized vs Paclitaxel	NCT01716715
Cabozantinib (XL184) Cometriq	Expanded Access		Approved for marketing	Medullary Thyroid Cancer (MTC)		NCT01683110
Cabozantinib (XL184) Cometriq	Efficacy	II	Recruiting	Advanced Urothelial Cancer		NCT01688999	ASCO 2013
Cabozantinib (XL184) Cometriq	Safety	I	Recruiting	Advanced Prostate Cancer	Docetaxel, Prednisone	NCT01683994	ASCO 2013
Cabozantinib (XL184) Cometriq	Safety/Efficacy	II	Completed	Metastatic Triple Negative Breast Cancer		NCT01738438
Cabozantinib (XL184) Cometriq	Safety/Efficacy	III	Recruiting	Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib	Randomized vs placebo	NCT01908426
Cabozantinib (XL184) Cometriq	Efficacy	II	Recruiting	Adults with Advanced Soft Tissue Sarcoma		NCT01755195
Cabozantinib (XL184) Cometriq	Safety/Efficacy	III	Active, not recruiting	Subjects with Metastatic Renal Cell Carcinoma	Randomized vs Everolimus	NCT01865747
Cabozantinib (XL184) Cometriq	Efficacy	II	Recruiting	Castrate Resistant Prostate Cancer with Visceral Metastases		NCT01834651
MSC2156119J same as: EMD1214063	Safety/Efficacy	I	Completed	Solid Tumors		NCT01832506
MSC2156119J	Safety	I	Recruiting	Advanced Solid Tumors		NCT01014936
MSC2156119J	Safety/Efficacy	I/II	Recruiting	Advanced NSCLC	+Gefitinib	NCT01982955
MSC2156119J	Safety/Efficacy	I/II	Recruiting	Asian Subjects with HCC	vs Sorafenib	NCT01988493
MSC2156119J	Safety/Efficacy	I/II	Recruiting	Second-Line HCC		NCT02115373
LY2875358	Efficacy	II	Recruiting	Gastric Cancer		NCT01874938	ASCO 2013
LY2875358	Safety	I	Recruiting	Advanced Cancer		NCT01287546
LY2875358	Efficacy	II	Recruiting	NSCLC	Erlotinib	NCT01900652
LY2875358	Safety/Efficacy	I/II	Recruiting	Advanced Cancer	Ramucirumab	NCT02082210
LY2875358	Safety	I	Recruiting	Japanese Participants with Advanced Cancer	alone, +Erlotinib, or +Gefitinib	NCT01602289
LY2875358	Efficacy	II	Recruiting	NSCLC with activating EGFR mutations	Erlotinib	NCT01897480
SAR125844	Safety	I	Completed	Advanced Malignant Solid Tumors with MET Amplification and Phospho-Met Positive Tumors Without MET Amplification		NCT01391533
SAR125844	Safety/Efficacy/Pharmacodynamics	I	Completed	Asian Advanced Malignant Solid Tumor Patients		NCT01657214
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Pharmacokinetics	I	Recruiting	Advanced Solid Tumors		NCT01773018
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Pharmacodynamics	I	Not Yet Recruiting	Ras Wild-Type Colorectal Cancer	Part 2 of study: Cetuximab	NCT02630420
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	II	Ongoing, Not Recruiting	Papillary Renal Cell Cancer		NCT02127710
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	Ib	Recruiting	EGFR Mutation Positive Advanced Lung Cancer	AZD9291	NCT02143466
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	II	Not Yet Recruiting	Advanced Gastric Adenocarcinoma Patients with MET Overexpression as a Second-line Treatment	Docetaxel	NCT02447380
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	Ib/II	Recruiting	Phase 1b in Any Solid Cancer and Sequential Phase II in Advanced Gastric Adenocarcinoma Patients with MET Amplification as a Second Line Treatment	Docetaxel	NCT02447406
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Pharmacokinetics/Preliminary Efficacy	1b	Recruiting	EGFR Mutation Positive NSCLC Patients that Progressed on EGFR TKI Treatment	Gefitinib	NCT02374645
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	II	Recruiting	Advanced Gastric Adenocarcinoma Patients with MET Amplification as a Third-line Treatment		NCT02449551
Volitinib Savolitinib AZD6094 HMPL-504 HMP-504	Safety/Efficacy	II	Recruiting	Locally Advanced or Metastatic Kidney Cancer	Randomized Muti-Arm Study Comparing Cabozantinib, Crizotinib, Volitinib or Sunitinib	NCT02761057
Met RNA CAR T cells	Safety/Efficacy	I	Recruiting	Metastatic Breast Cancer Triple Negative Breast Cancer		NCT01837602

**Trials listed here are for cancers where activation of the HGF/Met signaling pathway is indicated. Crizotinib (PF02341066) also potently inhibits anaplastic lymphoma kinase (Alk), and several trials currently underway are specific for tumors where Alk is activated. Crizotinib clinical trials where Alk activation is a criterion for eligibility are not included here.

HGF/Met Clinical Trial Metrics:

Agents	28
Trials	229
Active	137
Recruiting	90
Closed	78
Reporting	75

Last updated by Fox, Susan (NIH/NCI) [E] on Mar 05, 2018